NASDAQ$CSCIF
Aeterna Zentaris Inc · Q2 2018 earnings
Q2 2018 earnings · · Investor relations
Headline financials
Revenue & EPS history
Aeterna Zentaris · Revenue · Quarterly
$168K
Q2 2018-30.9%vs Q2 2017
Revenue by segment
Aeterna Zentaris · $2.75M total across 2 segments · Q2 2025
- Active Ingredients$2.42M—87.9%
- Pharmaceutical$332K—12.1%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2018
+0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.3%
Avg return
30 days after
42%
22 / 52 earnings
Positive
+43.3%
Q1 2020
Best reaction
-13.1%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | +0.0% | -24.9% | -25.7% | |
| Q1 2025 | +0.0% | +0.3% | +2.2% | |
| Q4 2025 | +1.4% | +0.4% | +26.3% | |
| Q3 2024 | -10.2% | -3.3% | -13.2% | |
| Q1 2024 | +3.0% | -10.5% | -36.1% | |
| Q2 2024 | +3.0% | -10.5% | -36.1% | |
| Q4 2023 | +9.5% | +4.5% | -2.0% | |
| Q3 2023 | -3.7% | +2.0% | +46.7% | |
| Q2 2023 | +0.0% | +1.4% | -15.6% | |
| Q1 2023 | -1.9% | -6.4% | -6.4% | |
| Q4 2022 | -0.4% | +0.4% | +16.6% | |
| Q3 2022 | +2.8% | -8.5% | +1.5% | |
| Q2 2022 | +5.0% | +10.0% | -5.2% | |
| Q1 2022 | +4.2% | -17.4% | -17.4% | |
| Q4 2021 | +1.5% | +2.8% | -16.7% | |
| Q3 2021 | -1.1% | -4.8% | -35.5% | |
| Q2 2021 | +3.4% | +2.8% | +2.8% | |
| Q1 2021 | -8.7% | -11.5% | -16.3% | |
| Q4 2020 | +11.8% | +2.7% | -14.5% | |
| Q3 2020 | -5.4% | +0.0% | +31.3% | |
| Q2 2020 | +7.6% | +15.2% | -13.0% | |
| Q1 2020 | +43.3% | +36.4% | +49.4% | |
| Q4 2019 | -6.9% | -14.5% | +47.3% | |
| Q3 2019 | +1.9% | -1.0% | -16.5% | |
| Q2 2019 | -4.0% | -6.3% | -16.5% | |
| Q1 2019 | -10.8% | -15.6% | -34.9% | |
| Q4 2018 | -3.1% | +11.0% | -6.9% | |
| Q3 2018 | -13.1% | -4.6% | +55.7% | |
| Q2 2018 | -2.4% | -6.5% | -12.1% | |
| Q1 2018 | -4.3% | -4.3% | +12.3% | |
| Q4 2017 | -9.6% | -17.9% | +3.1% | |
| Q3 2017 | +4.2% | +5.8% | +18.0% | |
| Q2 2017 | +13.3% | +15.0% | +2.2% | |
| Q1 2017 | -5.7% | -5.6% | +22.5% | |
| Q4 2016 | +1.7% | +0.0% | +2.8% | |
| Q3 2016 | -1.4% | +0.0% | +5.7% | |
| Q2 2016 | -1.7% | +2.8% | +6.3% | |
| Q1 2016 | +9.4% | — | — | |
| Q4 2015 | -3.0% | — | — | |
| Q3 2015 | -5.2% | — | — | |
| Q2 2015 | -13.0% | — | — | |
| Q1 2015 | -5.9% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2014 | +12.2% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | +3.7% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q2 2010 | -11.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro